Latin America Chemiluminescence Immunoassay Market is expected to reach US$ 955.12 Million by 2031

Oncology Segment to Lead Latin America Chemiluminescence Immunoassay Market Based on Application During 2023–2031

According to our new research study on “Latin America Chemiluminescence Immunoassay Market Forecast to 2031 – Regional Analysis – by Application and End User,” the market was valued at US$ 497.67 million in 2023 and is projected to reach US$ 955.12 million by 2031; it is expected to register a CAGR of 8.6% from 2023 to 2031. Key factors fueling the Latin America chemiluminescence immunoassay market growth include the rising incidence of infectious diseases and the growing use of point-of-care diagnostics. Moreover, technological advancements are projected to bring new Latin America chemiluminescence immunoassay market trends in the coming years.

The Latin America chemiluminescence immunoassay (CLIA) market has emerged as a significant sector within the region's healthcare and diagnostic landscape. This innovative technology, which combines chemiluminescence reactions with immunoassay principles, offers enhanced sensitivity and specificity for the detection of various biomarkers, making it a pivotal tool in clinical laboratories. The growing prevalence of chronic diseases such as diabetes, cardiovascular disorders, and infectious diseases has fueled the demand for accurate and rapid diagnostic tests, leading to an increased adoption of CLIA techniques across Latin American countries. Moreover, the region's expanding healthcare infrastructure and rising investments in medical diagnostics are further bolstering market growth. Key players in the industry are focusing on developing advanced CLIA systems that offer improved efficiency, automation, and ease of use, catering to the needs of both large and small healthcare facilities.

Latin America Chemiluminescence Immunoassay Market, by Application Segment, (%)

Source: The Insight Partners Analysis

Additionally, the ongoing advancements in technology, including the integration of artificial intelligence and data analytics within CLIA platforms, are enhancing diagnostic capabilities and fostering personalized medicine approaches. However, challenges such as regulatory hurdles, infrastructure disparities, and varying levels of healthcare access across different countries may impact the market's expansion. Despite these obstacles, the Latin America chemiluminescence immunoassay market size is poised for robust growth, driven by the increasing emphasis on early disease detection, advancements in diagnostic technologies, and a rising awareness of the importance of preventive healthcare measures. As healthcare providers and laboratories continue to adopt innovative solutions to meet the growing demand for accurate and timely diagnostics, the CLIA market in Latin America is set to play a crucial role in improving patient outcomes and overall public health.

Latin America Chemiluminescence Immunoassay Market Analysis Based on Segmental Evaluation:

The Latin America chemiluminescence immunoassay market report is categorized on the basis of application and end user. By application, the Latin America chemiluminescence immunoassay market is segmented into oncology, fertility, endocrinology, cardiology, infectious diseases, diabetes, and others. Based on end user, the market is categorized into hospitals, blood banks, clinical laboratories, pharmaceutical & biotech companies, and others.

In 2023, the oncology segment held the largest Latin America chemiluminescence immunoassay market share and the fertility segment is expected to register the highest CAGR in the market during 2023–2031. According to the Lancet, ~1.5 million new cancer cases and ∼700,000 cancer-related deaths are annually recorded in Latin America and the Caribbean (LAC) region. According to the World Health Organization, in Brazil, cancer is ranked as the second-leading cause of death, resulting in 227,920 deaths in 2018. It also reports that the age-adjusted death rate due to cancer is 111 per 100,000 for men and 95 per 100,000 for women. According to the Revista Brasileira de Cancerologia, nearly 704,000 new cancer cases were reported in Brazil in 2023. For instance, the EDI Human Chromogranin A CLIA Kit is indicated for the quantitative detection of human chromogranin A (CgA) levels in serum using the ECL100 or ECL25 immunoassay analyzer. This test may be used as an aid to detect patients with pheochromocytoma and neuroendocrine tumors (such as carcinoids).

According to the National Institutes of Health (NIH), ~188 centers in 16 countries reported 87,732 females had their first menstrual cycles in 2020, and 12,778 childbirths and 14,405 live births were recorded in Latin America. According to the Comisión Económica para América Latina y el Caribe, the total fertility rate (TFR) of Latin America, which fell below replacement level in 2015, was estimated at 1.85 live births per woman in 2022, with a further projection to drop to 1.68 by 2100. There has also been an increase in the average age of fertility. The Biopanda Prolactin chemiluminescence immunoassay test kit provides a means for the quantitative determination of prolactin in human serum. Chemiluminescent immunoassay has replaced radioimmunoassay in the measurement of serum progesterone as a current standard owing to factors such as high correlation and increased practicality.

Based on end user, the hospital segment held the largest Latin America chemiluminescence immunoassay market share in 2023. The clinical laboratories sector segment is expected to register the highest CAGR in the market during 2023–2031. Immunodiagnostics tests are performed in different hospital departments, including clinical microbiology labs, pathological labs, serological labs, histopathology and hematology sections, clinical biochemistry labs, and hospital wards. A few immunodiagnostic instruments provide quick results, while samples are sent to specialized laboratories in the case of complex tests. The rising demand for point-of-care (POC) immunoassay testing products in hospital settings benefits the CLIA market. At present, CLIA tests are employed to detect tumor markers and diagnose infectious diseases, endocrine disorders, diabetes, and so on. With such varied applications in one automated system, CLIA systems find significant applicability in hospitals.

Diagnostic laboratories, built in adherence to domestic or international regulatory requirements, use CLIA-based kits and instruments for providing diagnostics services to hospitals, clinics, at-home care setups, etc. The surging prevalence of chronic and infectious diseases in Latin America and the practice of outsourcing immunodiagnostics procedures are the factors supporting the CLIA immunoassay market growth in the diagnostic laboratories segment.

Sysmex Corp, Shenzhen Mindray Bio-Medical Electronics Co Ltd, Bio-Rad Laboratories Inc, Merck KGaA, Abbott Laboratories, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, DiaSorin SpA, Siemens Healthineers AG, and Getein Biotech Inc. are among the leading companies profiled in the Latin America chemiluminescence immunoassay market report.

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com